A61T (p.Ala61Thr) variant of NRXN2 (Neurexin-2)
A61T (p.Ala61Thr) in NRXN2 (Neurexin-2) is a missense change. Clinical records from UniProt describe it as variant assessed as somatic; moderate impact. The available variant effect predictions contribute to a CATVariant prioritization score of 0.30 / 1. The record also includes population frequency data and structural context.
A61T (p.Ala61Thr) variant details
- p.Ala61Thr
- NCI-TCGA TCGA novel
- Variant assessed as somatic; moderate impact.
- Missense
- Variant Prioritization Score for Impact Estimate 0.299
- REVEL 0.18
- MetaLR 0.30
- MetaSVM -0.68
- CADD 18.80
- PolyPhen-2 0.07
- SIFT 0.34
- UniProt: Variant assessed as somatic; moderate impact.
- Population evidence available
- Structural context available